RecruitingNCT06887907

Phenotypic and Transcriptomic Description of Megakaryocytes in Sickle Cell Patient

Sponsor

University Hospital, Toulouse

Enrollment

40 participants

Start Date

Mar 13, 2025

Study Type

OBSERVATIONAL

Conditions

Sickle Cell Disease (SCD)

Summary

Sickle cell disease is the most common inherited blood disorder in the world. Chronic hemolysis induces platelet activation and chronic inflammation. Platelets and megakaryocyte, as medullar platelets precursors, are known to play a role in innate immunity. Little is known about the role of megakaryocytes at basal state and during acute complication in sickle cell disease patients. The aim of this study is to evaluate the role of megakaryocytes in sickle cell disease.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a new treatment for people with sickle cell disease (scd). The study is currently recruiting participants at 1 location. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.